Physician profile
Sunil C Patel
NPI 1033189584
$6,389.10
in general payments reported to CMS, 2019-2025
41 companies · $1,593 in 2025
The $1,593 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $718 · 2020: $388 · 2021: $513 · 2022: $616 · 2023: $1,032 · 2024: $1,529 · 2025: $1,593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,010 · Education: $143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,010.11 |
| Education | $143.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $961.88 | 2019-2025 | |
| Janssen Biotech, INC. | $739.99 | 2019-2025 | Darzalex, Talvey, Tecvayli |
| Astrazeneca Pharmaceuticals LP | $500.59 | 2019-2025 | Tagrisso, Lynparza, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $449.53 | 2019-2025 | Opdivo, Opdualag, Reblozyl |
| Celgene Corporation | $440.59 | 2020-2025 | Pomalyst, Reblozyl, Pomalyst |
| Genzyme Corporation | $358.09 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $328.73 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Novartis Pharmaceuticals Corporation | $259.50 | 2019-2025 | |
| Amgen INC. | $234.80 | 2019-2023 | Blincyto, Kyprolis |
| Genentech USA, INC. | $231.20 | 2019-2022 | |
| Abbvie INC. | $182.30 | 2019-2025 | |
| Seagen INC. | $154.32 | 2023-2024 | Padcev, Adcetris |
| Eisai INC. | $149.20 | 2024-2025 | |
| Array Biopharma INC | $135.17 | 2022-2025 | Braftovi, Mektovi, Tukysa |
| Pharmacosmos Therapeutics INC. | $105.75 | 2024-2025 | Monoferric |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $103.19 | 2019-2025 | |
| Astellas Pharma US INC | $93.92 | 2022-2024 | Xtandi, Xospata |
| Amneal Pharmaceuticals LLC | $91.86 | 2023-2025 | Neulasta, Avastin, Neupogen |
| Sobi, INC | $89.63 | 2022-2025 | |
| Ipsen Biopharmaceuticals, INC | $78.41 | 2023-2025 | Onivyde, Somatuline Depot, Tazverik |
| Lilly USA, LLC | $66.77 | 2019-2025 | Verzenio, Jaypirca |
| Caris Mpi, INC. | $64.55 | 2025 | Mi Cancer Seek |
| Janssen Pharmaceuticals, INC | $61.53 | 2020-2024 | Xarelto |
| Incyte Corporation | $56.50 | 2024-2025 | Jakafi |
| Takeda Pharmaceuticals U.S.A., INC. | $44.43 | 2019-2020 | |
| Dendreon Pharmaceuticals LLC | $43.62 | 2025 | Provenge |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.00 | 2019 | |
| Emd Serono, INC. | $39.09 | 2023-2025 | Bavencio |
| Jazz Pharmaceuticals INC. | $34.70 | 2024-2025 | |
| Recordati_rare_diseases_inc. | $32.18 | 2024 | Sylvant |
| Adaptive Biotechnologies Corporation | $29.19 | 2025 | Clonoseq |
| Agios Pharmaceuticals, INC. | $28.51 | 2025 | Pyrukynd |
| Kyowa Kirin, INC. | $26.46 | 2023 | Poteligeo |
| Davol INC. | $22.22 | 2021 | |
| Myovant Sciences INC. | $18.83 | 2021 | |
| Exelixis INC. | $18.64 | 2024 | Cabometyx |
| Regeneron Healthcare Solutions, INC. | $17.17 | 2025 | Libtayo |
| Foundation Medicine, INC. | $15.10 | 2023 | |
| Dova Pharmaceuticals | $13.79 | 2019 | |
| Mirati Therapeutics, INC. | $13.65 | 2023 | Krazati |
| Teva Pharmaceuticals USA, INC. | $13.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.